Increased prevalence of the cancer disease is the major reason for the growth of the global in-situ hybridization market. As per WHO estimations, by 2025, approximately 19.3 million new cancer cases are expected to occur every year. By a study done by GLOBOCAN, 8.2 million cancer-related deaths were recorded, globally in 2012. In-situ hybridization finds the highest application in the diagnosis and management of cancer disease. Thus, the increase in the prevalence of cancer disease across the globe is expected to be the key driver for the global in-situ hybridization market.
Ask for the Customized Reports Depending on the Requirement of the Business @
http://www.micromarketmonitor.com/contact/5740146856-request_for_customization.html
Extensive studies conducted over the last two decades regarding the genetic aberrations related to human diseases have recognized recurrent genomic abnormalities as potential driving factors for a variety of cancers. As a result of this, the researchers and cancer centers are embracing personalized medicines approach for cancer treatment through technologies, such as microarrays and next-generation sequencing using novel biomarkers. The in-situ hybridization assays help in joining the immunohistochemistry (IHC) and DNA FISH to complete the in-situ tool set for cancer researchers to discover, develop, and implement a new generation of tissue and cell-based diagnostics. Direct imaging of gene expression in-situ at the RNA level delivers a unique insight into the interplay between cancer cells and the tumor micro-environment, while cancer is in progression.
Speak to Analyst@
http://www.micromarketmonitor.com/contact/5740146856-speak_to_analyst.html
Emergence of new technologies for fast hybridization and quantification of the genome during the procedure of in-situ hybridization is expected to create great opportunities for the growth of the global in-situ hybridization market. For instance, RNAscope in-situ assay developed by Advanced Cell Diagnostics is capable of detecting every gene in-situ in human transcriptome and quantify multiple mRNA transcripts simultaneously, at a single cell level. It is applicable to all sample types and is used for fully-automated, sensitive, and fast assay development.
The main companies operating in the global in-situ hybridization market are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Agilent Technologies, Inc. (U.S.).
